Skip to content

Inflammatory Biomarkers for the Diagnosis of oPRES

Inflammatory Biomarkers for the Diagnosis of Obstetric Posterior Reversible Encephalopathy Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05433870
Enrollment
621
Registered
2022-06-27
Start date
2022-07-01
Completion date
2022-07-31
Last updated
2022-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Biomarkers, Neutrophil-lymphocyte Ratio, Posterior Reversible Encephalopathy Syndrome

Brief summary

The purpose of this study is to explore the inflammatory biomarkers for the diagnosis of obstetric posterior reversible encephalopathy syndrome.

Detailed description

The investigators retrospectively collected data (General information, clinical data, biochemical indicators, imaging features, and pregnancy outcome) from pregnant woman diagnosed with PRES to explore the inflammatory biomarkers for the diagnosis of oPRES during 2012 to 2021.Then, the investigators grouped all the patients into PRES group (PE or E with PRES) and NOT-PRES group (PE or E without PRES) according to the diagnostic criteria of PRES. Then, the investigators analysed the inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), and so on of two groups, and compared the difference of tow groups.

Interventions

OTHERWhether the PE or E patient combined with PRES

According to the Diagnostic criteria of PRES, all the patients grouped into two groups.

Sponsors

Dunjin Chen
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Pregnant women were diagnosed of PE or E. 2. All patients were examined the cranial imaging (MRI or CT), and imaging findings meeting the diagnostic criteria of PRES or normal. 3. all patients provided written informed consent.

Exclusion criteria

1. patients combined with other neurological disorders 2. patients combined with mental illness

Design outcomes

Primary

MeasureTime frameDescription
inflammatory biomarkersInflammatory biomarkers were collected within 1 day after the onset of symptoms.The values of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio will be measured.
cranial ImagingCranial Imaging was examined within 3 days after the onset of symptoms, such as s headaches, visual changes, seizures, consciousness impairment.According to the cranial Imaging, PE or E patients were grouped into PRES group (typical features presence of vasogenic edema in the white matter of the portions of both cerebral hemispheres) and NOT-PRES group (imaging findings were normal).

Secondary

MeasureTime frameDescription
other biochemical parametersbiochemical parameters were collected within 1 week of the hospital stay.The levels of C-Reactive protein (CRP) will be measured,and CRP﹥8000μg/L means a worse outcome.
Blood Pressure(BP)The BP of patients was obtained within 1hour after the onset of symptoms.blood pressure including systolic blood pressure (SBP), and diastolic blood pressure (DBP).
pregnancy outcomesThe pregnancy outcomes will record immediately when the patients deliver.The rates of stillbirth and premature birth (gestation less than 37 weeks) in PRES patients.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026